|Day Low/High||89.39 / 90.28|
|52 Wk Low/High||58.59 / 98.97|
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's check out the charts of BMY.
These two firms have successful drugs and could make nice additions for larger companies.
This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.
RMPIA outperformed once gain during April.
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
However, the RMPIA did not see as much improvement last month as some other market indices.
Experts offer their top stock ideas in oncology detection and treatment.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
The RMPIA rose 10.5% during the first half of the current quarter.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
Many see the Fed as done for the year. Never assume. Read the words as they are written.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.